TONIX PHA.NEW2023 DL-,001
TONIX PHA.NEW2023 DL-,001
Share · US8902608541 · TNXP · A3EDH2 (XNCM)
Overview Financial Indicators
35,20 EUR
4,18 % 1,41 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 23:59

Current Prices from TONIX PHA.NEW2023 DL-,001

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
TNXP
USD
06.06.2025 23:59
40,10 USD
38,39 USD
+4,45 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-0,49 % 1,13 % 107,16 % 197,36 % 102,88 % -88,58 % -99,99 %

Company Profile for TONIX PHA.NEW2023 DL-,001 Share

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Company Data

Name TONIX PHA.NEW2023 DL-,001
Company Tonix Pharmaceuticals Holding Corp.
Symbol TNXP
Website https://www.tonixpharma.com
Primary Exchange XNCM Frankfurt
WKN A3EDH2
ISIN US8902608541
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Seth Lederman M.D.
Market Capitalization 111 Mio
Country United States of America
Currency EUR
Employees 0,1 T
Address 26 Main Street, 07928 Chatham
IPO Date 2012-05-10

Stock Splits

Date Split
05.02.2025 1:100

Ticker Symbols

Name Symbol
NASDAQ TNXP

More Shares

Investors who TONIX PHA.NEW2023 DL-,001 hold also have the following shares in their portfolio:
BondBloxx ETF Trust BondBloxx USD High Yield Bond Telecom, Media & Technology Sector ETF
BondBloxx ETF Trust BondBloxx USD High Yield Bond Telecom, Media & Technology Sector ETF ETF
PORTUGAL 06-37
PORTUGAL 06-37 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025